机构:[1]ShangHai Pulm Hosp, Shanghai, Peoples R China[2]Second Peoples Hosp Hunan Prov, Changsha, Peoples R China[3]Huazhong Univ Sci & Technol, Tongji Med Coll, Wuhan, Peoples R China[4]Zhejiang Canc Hosp, Hangzhou, Peoples R China浙江省肿瘤医院[5]Anhui Chest Hosp, Hefei, Peoples R China[6]Cent South Univ, Xiangya Hosp, Changsha, Peoples R China[7]Harbin Med Univ, Canc Hosp, Harbin, Peoples R China[8]Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hangzhou, Peoples R China浙江大学医学院附属第一医院[9]Shandong Canc Hosp, Jinan, Peoples R China[10]First Hosp Jilin Univ, Changchun, Peoples R China[11]Taihe Hosp, Shiyan, Peoples R China[12]Nanjing Chest Hosp, Nanjing, Peoples R China[13]Liuzhou Peoples Hosp, Liuzhou, Peoples R China[14]Xinxiang Med Univ, Affiliated Hosp 1, Xinxiang, Henan, Peoples R China[15]302 Hosp PLA, Beijing, Peoples R China[16]Chongqing Med Univ, Affiliated Hosp 1, Chongqing, Peoples R China重庆医科大学附属第一医院[17]Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China[18]Henan Canc Hosp, Zhengzhou, Peoples R China河南省肿瘤医院[19]Sichuan Canc Hosp, Chengdu, Peoples R China四川省肿瘤医院[20]Henan Univ Sci & Technol, Affiliated Hosp 1, Luoyang, Peoples R China[21]Peking Univ, Canc Hosp, Beijing, Peoples R China[22]Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Hangzhou, Peoples R China[23]Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China[24]Southern Med Univ, Nanfang Hosp, Guangzhou, Peoples R China[25]Guangdong Med Univ, Affiliated Hosp, Zhanjiang, Peoples R China[26]Shanghai Fosun Pharmaceut Ind Dev Co Ltd, Shanghai, Peoples R China
第一作者机构:[1]ShangHai Pulm Hosp, Shanghai, Peoples R China
推荐引用方式(GB/T 7714):
Xiong A.,Yang N.,Dong X.,et al.Randomized, Open-Label, Phase III Study of SAF-189s Versus Crizotinib in First-Line ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)[J].JOURNAL OF THORACIC ONCOLOGY.2024,19(10):S27-S28.
APA:
Xiong, A.,Yang, N.,Dong, X.,Fan, Y.,Xu, L....&Zhou, C..(2024).Randomized, Open-Label, Phase III Study of SAF-189s Versus Crizotinib in First-Line ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC).JOURNAL OF THORACIC ONCOLOGY,19,(10)
MLA:
Xiong, A.,et al."Randomized, Open-Label, Phase III Study of SAF-189s Versus Crizotinib in First-Line ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)".JOURNAL OF THORACIC ONCOLOGY 19..10(2024):S27-S28